[ OrphoMed raises $39M in Series A ]
OrphoMed has raised $39 million in Series A funding.
Founded in 2015, OrphoMed is a biopharmaceutical company that develops dimer therapies for visceral hypersensitivity and hypermotility in gastrointestinal disorders.
The cnew financing will be used to advance the clinical development of OrphoMed’s lead candidate, ORP-101, for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
|City||Mill Valley, California|
|Founder / CEO||Nikhilesh Singh|
|Investors||New Enterprise Associates|
|Relativity Healthcare Partners|
|Mario Family Funds|